|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Tax credit receivable | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Non-Current Assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Right of use asset | ||||||||||||||||||||
| In-process research and development | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Deposits and other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities and Stockholders' Equity | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Contingent consideration, current portion | ||||||||||||||||||||
| Accrued employee benefits | ||||||||||||||||||||
| Deferred research and development tax credit-current portion | ||||||||||||||||||||
| Loans payable-current | ||||||||||||||||||||
| Operating lease liability-current portion | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Non-current Liabilities | ||||||||||||||||||||
| Non-current contingent consideration | ||||||||||||||||||||
| Loan Payable - non-current | ||||||||||||||||||||
| Deferred tax liabilities, net | ||||||||||||||||||||
| Non-current deferred research and development tax credit | ||||||||||||||||||||
| Non-current operating lease liability | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Convertible preferred stock | ||||||||||||||||||||
| Series C convertible preferred stock | ||||||||||||||||||||
| Series D convertible preferred stock | ||||||||||||||||||||
| Stockholders' Equity: | ||||||||||||||||||||
| Common stock, $0.001 par value; 350,000,000 shares authorized, 45,921,478 issued and 45,892,668 outstanding at June 30, 2026 and 35,717,159 issued and 35,688,350 outstanding at December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Treasury stock at cost, 28,810 shares at June 30, 2026 and at December 31, 2025 | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders' Equity | ||||||||||||||||||||
Loading...
